Garsorasib治疗KRAS G12C突变非小细胞肺癌:1/2期研究汇总分析
该汇总分析纳入189例KRAS G12C突变晚期非小细胞肺癌患者,接受garsorasib 600mg每日两次治疗。客观缓解率48.1%,疾病控制率87.8%,中位无进展生存期9.07个月,中位总生存期14.19个月。安全性可控,未发现新安全性信号。
要点
- 客观缓解率达48.1%,疾病控制率87.8%
- 中位无进展生存期9.07个月,中位总生存期14.19个月
- ≥3级治疗相关不良事件发生率49.2%,安全性总体可控
核心结论
- 汇总分析证实garsorasib在KRAS G12C突变非小细胞肺癌中具有稳健疗效和可控安全性。
研究设计与样本
- 多中心、开放标签1/2期研究汇总分析,纳入189例KRAS G12C突变局部晚期或转移性非小细胞肺癌患者(1期66例,2期123例)。
- 汇总接受garsorasib 600mg每日两次治疗的患者数据,中位随访时间13.0个月(IQR 6.7-17.5)。
主要发现
- 客观缓解率48.1%(95%CI 40.8-55.5),疾病控制率87.8%(95%CI 82.3-92.1)。
- 中位缓解持续时间12.45个月(95%CI 8.31-14.49),中位无进展生存期9.07个月(95%CI 7.39-9.76),中位总生存期14.19个月(95%CI 13.08-17.54)。
- 任何级别治疗相关不良事件发生率96.3%,≥3级发生率49.2%,未观察到新安全性信号,多数不良事件可控。
临床怎么用
- garsorasib 600mg每日两次可作为KRAS G12C突变晚期非小细胞肺癌的治疗选择,需关注≥3级不良事件的监测与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Garsorasib, a KRAS G12C inhibitor, has previously demonstrated its efficacy and safety in patients with KRAS G12C-mutated non-small-cell lung cancer (NSCLC). Here, we present long-term follow-up data from a pooled analysis of the phase 1/2 study. METHODS: This multicenter, open-label phase 1/2 study enrolled patients with KRAS G12C-mutated, locally advanced or metastatic NSCLC. The primary endpoints for phase 1 were safety and tolerability and for phase 2 objective response rate (ORR) by a blinded independent review committee per RECIST version 1.1. Data was pooled from patients who received garsorasib 600 mg twice daily. RESULTS: This pooled dataset included 189 patients (N = 66 in phase 1 and N = 123 in phase 2). The median pooled follow-up time was 13.0 months (IQR: 6.7-17.5). The objective response rate was 48.1 % (95 %CI: 40.8-55.5), and disease control rate was 87.8 % (95 %CI: 82.3-92.1). The median duration of response was 12.45 months (95 % CI: 8.31, 14.49), the median progression-free survival was 9.07 months (95 %CI: 7.39-9.76), and the median overall survival was 14.19 months (95 %CI: 13.08-17.54). Treatment-related adverse events of any grade occurred in 96.3 % of patients, with grade ≥ 3 in 49.2 % of patients. No new safety findings were observed, and most of the adverse events were controllable. CONCLUSION: This pooled analysis confirmed the robust efficacy and manageable safety of garsorasib in KRAS G12C-mutated NSCLC. GOV IDENTIFIER: NCT05383898.
引用
- Song Z, Li Z, Zhang Y, et al. Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study. Eur J Cancer. 2025. PMID: 41330054. doi:10.1016/j.ejca.2025.116153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。